Mequinol/tretinoin

Drug Profile

Mequinol/tretinoin

Alternative Names: 4-HA/tretinoin; 4-hydroxyanisole; 4-hydroxyanisole/tretinoin; BMS 181158; BMS 181158/BMS 181159; BMS 181159; Solage®; Solagé; Solagé Topical Solution; Tretinoin/mequinol

Latest Information Update: 14 Aug 2013

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anisoles; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Hyperpigmentation; Melanosis

Most Recent Events

  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
  • 06 Aug 2008 Barrier Therapeutics Inc has been acquired by Stiefel Laboratories
  • 02 May 2005 Barrier Therapeutics and Ventiv Health have entered into an agreement to co-promote Solage® in USA for solar lentigines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top